As founders, we work side-by-side with our entrepreneurs to
build companies around innovative science.
Pioneering targeted therapies
for serious muscle diseases –
IPO Sep 2020 (NASDAQ: DYN)
Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)
Breakthrough therapies for neuro-
logical & psychiatric conditions
– Sold to Novartis Dec 2020
Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics
Harnessing the power of microglia to
transform treatments for neuro-
degenerative diseases (NASDAQ: VIGL)
Restoring metabolic balance to treat
NASH and serious metabolic diseases
– IPO Jun 2019 (NADSAQ: AKRO)
Advancing targeted protein
degradation to target previously
“undruggable” disease pathways
Harnessing the immune system to
defeat cancer with tumor-selective
immunotherapies (NASDAQ: XLO)
Broadening the reach and
impact of precision medicine
to more people with cancer
Targeting the DNA damage
response pathway to prevent and
halt expansion repeat disorders
Enhancing synaptic integrity for
treatment of neurologic dis-
orders; sold to Alkermes Nov 2019
Preventing axonal degeneration in
patients with neurological diseases
Sold to Lilly (NYSE: LLY) Oct 2020
Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016
Delivering medicines for rare,
autoimmune, and inflammatory diseases
IPO July 2011 (NASDAQ: HZNP)
Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)
Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)
Treating cancer’s toughest
tumors by harnessing the power
of precisely delivered radiation
Patient-directed oncology therapies
across immune and cancer cell pathways
IPO Mar 2021 (NASDAQ: IKNA)
Scalable, re-dosable, non-viral
gene therapy for genetic diseases
IPO Jun 2020 (NASDAQ: GBIO)
Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)
Advancing novel therapies for people
with rare cardiopulmonary disease
– IPO Jun 2021 (NASDAQ: AVTE)
Novel bicyclic peptides (bicycles) and
bicycle drug conjugates for cancer
IPO May 2019 (NASDAQ: BCYC)
Rapidly developing new cancer
treatments for people of all ages
– IPO Jun 2021 (NASDAQ: DAWN)
Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016